QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mao, J.-H. Articles by Balmain, A. Search for Related Content PubMed PubMed Citation Articles by Mao, J.-H. Articles by Balmain, A. Social Bookmarking                   What's this?

RESEARCH COMMUNICATION

Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression

University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94143, USA

	Abstract

Top Abstract Results and Discussion Materials and methods Acknowledgments References

 
Pten heterozygous (Pten^+/-) mice develop increased papilloma numbers and show decreased carcinoma latency time in comparison with controls after skin treatment with dimethyl benzanthracene (DMBA) and tetradecanoyl-phorbol acetate (TPA). H-ras mutation is normally a hallmark of DMBA-TPA-induced skin tumors, but 70% of carcinomas from Pten^+/- mice do not exhibit this mutation, and in all cases have lost the wild-type Pten allele. Tumors that retain the Pten wild-type allele also have H-ras mutations, indicating that activation of H-ras and complete loss of Pten are mutually exclusive events in skin carcinomas. Mitogen-activated protein kinase (MAPK) is consistently activated in the tumors with H-ras mutations, but is strongly down-regulated in Pten^-/- tumors, suggesting that this pathway is dispensable for skin carcinoma formation. These data have important implications in designing individual therapeutic strategies for the treatment of cancer.

[Keywords: Pten; ras; Akt; skin; papilloma; carcinoma]

Received April 21, 2004; revised version accepted June 2, 2004.

We have used dimethyl benzanthracene (DMBA)-tetradecanoyl-phorbol acetate (TPA)-induced skin carcinogenesis to study the molecular mechanisms that underlie the development of this malignancy. A signature of DMBA treatment is an activating mutation in H-ras, which is the most common initiating event for tumor formation (Balmain et al. 1984; Quintanilla et al. 1986). We demonstrate here that most skin carcinomas from Pten^+/- mice do not have this signature mutation, but instead show complete loss of Pten by deletion of the wild-type allele. These genetic changes are correlated with major differences in signaling through the mitogen-activated protein kinase (MAPK) and PI3K/Akt pathways.

	Results and Discussion

Top Abstract Results and Discussion Materials and methods Acknowledgments References

 
To investigate the role of Pten in skin carcinogenesis, we treated an equal number of Pten^+/- mice and wild-type littermates with DMBA and TPA. We used germ-line Pten^+/- mice (Di Cristofano et al. 1998), as opposed to tissue-specific knockout (KO) models (Suzuki et al. 2003) to better recapitulate the condition of CD. The basal level of Pten protein is clearly reduced in the skin of these heterozygous animals (Fig. 1A), and this is relevant given that Pten expression is rapidly up-regulated, both at the RNA and protein levels, in response to TPA treatment (Fig. 1B). The increase in levels of a tumor suppressor protein such as Pten is intriguing in view of the fact that TPA treatment strongly induces proliferation in the epidermis. A similar situation is, however, seen with other negative growth regulators such as TGF (Akhurst et al. 1988), which are also induced in response to TPA treatment, possibly as part of a mechanism that ensures a regulated return to homeostatic equilibrium within the epidermis. In light of these observations, we predicted Pten^+/- mice to be more susceptible to DMBA-TPA-induced skin carcinogenesis, although the risk of spontaneously developing skin cancer was not noticeably altered (Di Cristofano et al. 1998; Podsypanina et al. 1999). Both Pten^+/- and wild-type mice developed papillomas after 7–8 wk of DMBA-TPA treatment. However, the papilloma number was significantly higher in Pten^+/- animals in comparison with wild type in both males and females (Fig. 1C). By 20 wk posttreatment, the mean number of papillomas per mouse was more than three-fold higher in Pten^+/- mice (p < 0.0001), indicating that loss of one Pten allele renders animals more susceptible to DMBA-TPA-induced skin carcinogenesis.

View larger version (44K): [in this window] [in a new window]   Figure 1. Pten heterozygosity increases skin cancer susceptibility. (A) Pten protein expression in the skin of wild-type and Pten+/- mice. (B) Expression of Pten is induced in wild-type mice at RNA (top) and protein (bottom) levels at indicated time points after TPA treatment. Pten protein levels in skin of two different mice are shown at each time point. (C) Average papilloma number per mouse at the indicated time points after DMBA-TPA treatment. (D) Latency of carcinoma onset.

A two-hit mechanism to inactivate tumor suppressor genes has been well documented, and Pten appears to follow this paradigm in many tumor types. We examined the status of Pten in skin tumors using microsatellite markers at, and also proximal and distal to, the Pten genomic locus. In 15 papillomas and 12 carcinomas from wild-type mice, we did not detect any deletions at the Pten locus. In contrast, loss of heterozygosity (LOH) was observed in papillomas and a high number of carcinomas from Pten^+/- mice (Fig. 2A). In many instances, LOH extends to markers as far as 20 cM from the Pten locus, and may reflect a loss of the entire chromosome 19. However, LOH at adjacent markers did not occur independently of LOH at the Pten locus, indicating that Pten is the primary target for LOH in these tumors.

View larger version (60K): [in this window] [in a new window]   Figure 2. H-ras and Pten alterations are mutually exclusive. (A) LOH analysis of tumors from Pten+/- mice using the indicated microsatellite markers on chromosome 19, as obtained from the Celera database. Papilloma #16 (fifth from the right) shows loss of distal markers on chromosome 19, but is wild type at Pten, and has a mutation in H-ras (Table 1). (B) Papillomas and carcinomas from wild type (top panel) and Pten+/- (bottom panel) were analyzed for H-ras mutation by digestion of PCR products as described in text, and for Pten expression by RT–PCR. Asterisk indicates samples with TTA alteration, as opposed to the more common CTA, at codon 61 of H-ras, and hence was not digested by XbaI. (C) Chromatogram showing the CAA TTA alteration at codon 61 of H-ras that occurred in a small number of papillomas.

View larger version (76K): [in this window] [in a new window]   Figure 3. H-ras activation and Pten inactivation elicit differential biochemical responses. The status of pten for each tumor, as determined by microsatellite and RT–PCR analysis, is indicated. (A) Pten and H-Ras protein levels in papillomas and carcinomas. (B) Separation of wild-type and mutant (Gln61Leu) H-Ras protein in carcinomas by high-percentage SDS-PAGE. (C) Analysis of Erk and Akt activation in papillomas and carcinomas using antibodies to detect phosphorylated and total protein, as indicated.

A lack of Pten alterations in tumors from wild-type mice was a surprising finding because homozygous inactivation of Pten in keratinocytes can clearly cause skin cancer (Suzuki et al. 2003). On the other hand, our data are consistent with findings in human skin tumors, where a lack of somatic Pten alterations has also been reported (Kubo et al. 1999). It is possible that inactivation of both Pten alleles is required during skin carcinogenesis, a situation that is more favorable when the first event has already occurred through germ-line transmission, as is the case with CD and Pten^+/- mice. In this respect, genetic alterations at other loci may substitute for Pten inactivation in tumors from wild-type mice and may even preclude the need for Pten LOH in some tumors from Pten^+/- animals.

Activating mutations in H-ras, usually a CAA-to-CTA change at codon 61, occur at a high frequency in DMBA-initiated skin tumors (Balmain et al. 1984; Quintanilla et al. 1986). H-Ras has a stimulatory effect on PI3K/Akt signaling; thus its activation could occur in place of Pten inactivation. We analyzed skin tumor DNA for H-ras-activating mutations, taking advantage of the XbaI restriction site created by the CTA mutation (Nagase et al. 2003). Activating H-ras mutations were detected in all 10 carcinomas from wild-type animals (Fig. 2B). In two papillomas where the mutant product was not detected, DNA sequencing revealed a TTA alteration at codon 61 in place of the more common CTA (Fig. 2C). Interestingly, both CTA and TTA alterations resulted in the same Gln61Leu amino acid change, pointing to importance and selectivity of this residue in activated H-Ras protein. Taken together, our data showed that the codon 61-activating H-ras mutation occurs in every DMBA-TPA-induced papilloma and carcinoma from wild-type mice.

In contrast, the majority of skin carcinomas derived from Pten^+/- mice did not carry this H-ras mutation, and all of the tumors in this category had undergone Pten LOH. We did not detect any mutations in H-ras despite sequencing the entire coding region. Because mutations in K-ras have been found in skin tumors from DMBA-TPA treated H-ras KO mice (Ise et al. 2000), we also sequenced the entire coding region of K-ras in these carcinomas and did not detect any mutation. There is therefore a highly significant correlation between the absence of ras mutations in carcinomas and the loss of the wild-type Pten allele. Table 1 summarizes results of Pten and H-ras status in papillomas and carcinomas from wild-type and Pten^+/- mice. It can be seen that although the majority of the benign papillomas in Pten^+/- mice still had activated H-ras in the usual manner, 30% had lost the Pten allele. Of these, two had both activated H-ras and loss of Pten, in contrast to the situation seen in the carcinomas. This may indicate that papillomas carrying both mutations are less likely to progress to malignancy than those showing complete loss of Pten.

We analyzed the status of downstream targets of H-Ras and Pten in order to better understand the biochemical consequences of their alterations. Several lines of evidence suggest that the activation of Erk-1 and Erk-2 MAPK proteins, which are important components of the H-Ras network, can also be dependent on the status of Pten (Shan et al. 2000; Suzuki et al. 2001, 2003). Despite relatively similar levels of total Erk proteins, the phosphorylated or active forms of both Erk proteins (P-Erk) were only detectable in papillomas or carcinomas that do not have complete Pten inactivation (Fig. 3C) and are most likely a direct consequence of the oncogenic H-Ras protein present in these tumors (see earlier). Even in these cases, the level of P-Erk proteins was barely detectable in papillomas. The Erk proteins are more strongly activated in carcinomas, which are consistent with the up-regulated mutant H-Ras expression in these malignant tumors, but the extent of activation can be variable. The almost complete lack of P-Erk in papillomas and carcinomas with complete Pten inactivation may be a signature of these tumors, and suggests that Erk activation is dispensable in skin carcinogenesis or at least during papilloma-to-carcinoma conversion.

Central to the tumor-suppressing function of Pten is the inhibition of Akt signaling (Stambolic et al. 1998). In contrast, H-Ras activates PI3K activity, which in turn stimulates the Akt pathway (Cox and Der 2003). We observed an increasing trend in levels of phosphorylated Akt (P-Akt) from papillomas to carcinomas as previously reported (Fig. 3C; Segrelles et al. 2002), suggesting that Akt activation is important for carcinoma development and consistent with the role of Akt signaling in promoting cell proliferation and survival (Vivanco and Sawyers 2002). Interestingly, whereas many studies with cultured cells have shown regulation of Akt signaling in response to Pten alterations to be largely at the level of phosphorylation (Stambolic et al. 1998; Suzuki et al. 2003), we found that in papilloma and particularly carcinoma specimens the regulation appears to occur at the level of total Akt protein as well. Tumors with retention of the wild-type Pten allele and carrying H-ras mutations in general had higher levels of total Akt protein. It is possible that these higher levels may be a consequence of the activity of Ras/MAP in inducing cell death (Deng et al. 2004), causing a feedback response leading to up-regulation of Akt-mediated survival signals. A dynamic balance between these opposing pathways may explain why no tumors carrying both genetic alterations have progressed to malignancy, whereas those with only Pten loss, and no MAPK activity, have high malignant potential. These results may be relevant to prognosis of human cancer carrying both kinds of genetic changes, which may be expected to have a more indolent growth pattern.

A lack of concurrent Pten alteration and N-ras or K-ras mutation has been reported for melanoma cell lines (Tsao et al. 2000) and endometrial cancer (Ikeda et al. 2000), respectively. However, the relationship between these mutational events is still unclear, and some melanomas or uncultured cells have been reported to have both mutations in B-raf and loss of Pten (Tsao et al. 2004). In this study, we have excluded the possibility that the common sites of activation of K-ras or B-raf (Davies et al. 2002) are mutated in the tumors that show complete loss of Pten (data not shown). We conclude that Pten inactivation and H-ras activation are mutually exclusive in malignant skin carcinomas, suggesting that these events are genetically redundant, and that alteration in both genes does not confer a further advantage. It is also possible that H-ras activation and Pten loss is in fact disadvantageous when these events occur together in the same cell. We detected two papillomas with both H-ras mutation and Pten inactivation, but no carcinomas with both changes. Although these numbers are small, papillomas with both genetic alterations are possibly at a relative disadvantage for tumor progression to carcinomas, possibly due to reported effects of activated ras in induction of apoptosis (Chang et al. 2003) or growth arrest (Serrano et al. 1997).

These observations of discrete pathways leading to malignancy in this model system have important implications for the design of therapeutic strategies for the treatment of skin cancer as well as other cancers with frequent Pten and/or ras alterations. Tumors with complete loss of Pten and low levels of signaling through the Ras/Raf/Erk pathway will obviously not respond to small molecule drugs that inhibit these targets. Such treatments may even be detrimental, because they may alter the balance between cell death and survival pathways in cancers carrying both mutations.

	Materials and methods

Top Abstract Results and Discussion Materials and methods Acknowledgments References

 

Mice and chemical carcinogenesis

Pten^+/- mice (C57BL/6), provided by Dr. P.P. Pandolfi (Memorial Sloan-Kettering Cancer Center, New York; Di Cristofano et al. 1998), were crossed with FVB/N to generate F1 wild-type and Pten^+/- mice. To induce skin carcinogenesis, we used a single dose of DMBA treatment followed by twice-weekly application of TPA for 20 wk as described (Balmain et al. 1984; Quintanilla et al. 1986). Papilloma number was recorded up to 20 wk and carcinoma development monitored up to 60 wk post-DMBA treatment. Mice were killed if moribund, if the tumor load was excessive, if any individual tumor exceeded 1.5 cm in diameter, or at the termination of the experiment. Surgically removed tumors were immediately snap-frozen in liquid nitrogen, and stored at -70°C. We scored tumors as carcinomas or papillomas on the basis of their morphological appearance and histological features.

DNA/RNA and protein preparation

Tumors were ground into a fine powder in liquid nitrogen and aliquotted for DNA and RNA extraction and protein lysate preparation. DNA was isolated using standard phenol/chloroform extraction following an overnight 55°C incubation with Proteinase K. Total RNA was purified using TRIzol Reagent (Invitrogen). For total protein lysates, powdered tumors were incubated in ice-cold lysis buffer (50 mM Tris-Cl at pH 7.4, 2 mM EDTA, 150 mM NaCl, 1% NP-40, 0.5% Triton X-100, 0.1% SDS) supplemented with Complete Mini Protease Inhibitor Cocktail (Roche). Soluble protein lysates were quantified using BCA Protein Assay kit (Pierce).

LOH analysis

Tumor and corresponding normal DNA was used for LOH studies with microsatellite markers at the Pten locus and flanking regions chosen from the Celera database. PCR amplification was performed in 20-µL volume containing 1x PCR buffer (Bioline), 200 µM of each dNTP (Pharmacia), 6.6 µM of each primer (Qiagen Operon), 1.5 mM MgCl₂, 2 units of Taq polymerase (Bioline), and 80 ng of DNA. Amplifications were initially denatured for 3 min at 94°C, followed by 35 cycles of 30 sec at 94°C, 30 sec at 55°C or 52°C, and 30 sec at 72°C. PCR products were electrophoresed in 4% (3% NuSieve/1% normal) agarose gel and visualized by ethidium bromide staining.

Pten expression analysis

RT–PCR was performed using Thermoscript RT–PCR (GIBCO-BRL). Mutation analysis of the Pten coding sequence was performed by direct sequencing of gel-purified PCR products of tumor cDNA. Primer pairs used in the analysis were Pten1F (5'-CATCTCTCTCCTCCTTTTTCT TCA-3') and Pten1R (5'-CAAACATCATCTTGTGAAACAGC-3'), Pten2F (5'-GGCAAATTTTTAAAGGCACAAG-3') and Pten2R (5'-AAGTTGA ACTGCTAGCCTCTGG-3'), and Pten3F (5'-ACTTTGAGTTCCCTCA GCCA-3') and Pten3R (5'-TTCATGGTATTTTATCCCTCTTGA-3').

Immunoblotting

Equal amounts of proteins were resolved by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membrane using standard protocol. We used 18% polyacrylamide gel in order to distinguish between wild-type and codon 61 H-Ras mutant protein. Rabbit polyclonal antibody to phospho-Ser 473–PKB/AKT was a gift from Dr. David Stokoe (University of California at San Francisco). We purchased Pten (A2B1), H-Ras (C-20), and ERK1 (C-16) antibodies from Santa Cruz Biotechnology, and P-Erk (#9101) and Akt (#9272) antibodies from Cell Signaling Technology.

Statistical analysis

SPSS statistical package was used for all statistical analysis. We used the nonparametric test to compare papilloma number and the Kaplan-Meire method to compare latency in progression to carcinoma.

	Acknowledgments

Top Abstract Results and Discussion Materials and methods Acknowledgments References

 
These studies were supported by NCI grant U01 CA84244 to A.B. The UCSF Cancer Center Genome Core was essential for the sequencing. Special thanks go to the University of California at San Francisco animal house staff, and to Dr. P.P. Pandolfi for kindly providing us with Pten KO mice. J.-H.M. is a recipient of a Leukemia & Lymphoma Society Fellowship. J.P.-L. has a Fellowship from the Ministerio de Educacion y Ciencia of Spain.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

	Footnotes

 
Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.1213804.

¹ These authors contributed equally to this work.

² Corresponding author. E-MAIL abalmain{at}cc.ucsf.edu; FAX (415) 502-6779.

	References

Top Abstract Results and Discussion Materials and methods Acknowledgments References

 
Akhurst, R.J., Fee, F., and Balmain, A. 1988. Localized production of TGF- mRNA in tumour promoter-stimulated mouse epidermis. Nature 331: 363-365.[CrossRef][Medline]

Balmain, A., Ramsden, M., Bowden, G.T., and Smith, J. 1984. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature 307: 658-660.[CrossRef][Medline]

Camisa, C., Bikowski, J.B., and McDonald, S.G. 1984. Cowden's disease. Association with squamous cell carcinoma of the tongue and perianal basal cell carcinoma. Arch. Dermatol. 120: 677-678.[CrossRef][Medline]

Chang, F., Steelman, L.S., Shelton, J.G., Lee, J.T., Navolanic, P.M., Blalock, W.L., Franklin, R., and McCubrey, J.A. 2003. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway Int. J. Oncol. 22: 469-480.[Medline]

Cox, A.D. and Der, C.J. 2003. The dark side of Ras: Regulation of apoptosis. Oncogene 22: 8999-9006.[CrossRef][Medline]

Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417: 949-954.[CrossRef][Medline]

Deng, Q., Liao, R., Wu, B.L., and Sun, P. 2004. High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J. Biol. Chem. 279: 1050-1059.[Abstract/Free Full Text]

Di Cristofano, A., Pesce, B., Cordon-Cardo, C., and Pandolfi, P.P. 1998. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19: 348-355.[CrossRef][Medline]

Groszer, M., Erickson, R., Scripture-Adams, D.D., Lesche, R., Trumpp, A., Zack, J.A., Kornblum, H.I., Liu, X., and Wu, H. 2001. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294: 2186-2189.[Abstract/Free Full Text]

Hennings, H., Shores, R., Mitchell, P., Spangler, E.F., and Yuspa, S.H. 1985. Induction of papillomas with a high probability of conversion to malignancy. Carcinogenesis 6: 1607-1610.[Abstract/Free Full Text]

Hildenbrand, C., Burgdorf, W.H., and Lautenschlager, S. 2001. Cowden syndrome-diagnostic skin signs. Dermatology 202: 362-366.[CrossRef][Medline]

Ikeda, T., Yoshinaga, K., Suzuki, A., Sakurada, A., Ohmori, H., and Horii, A. 2000. Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer. Oncol. Rep. 7: 567-570.[Medline]

Ise, K., Nakamura, K., Nakao, K., Shimizu, S., Harada, H., Ichise, T., Miyoshi, J., Gondo, Y., Ishikawa, T., Aiba, A., et al. 2000. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 19: 2951-2956.[CrossRef][Medline]

Kubo, Y., Urano, Y., Hida, Y., and Arase, S. 1999. Lack of somatic mutation in the PTEN gene in squamous cell carcinomas of human skin. J. Dermatol. Sci. 19: 199-201.[CrossRef][Medline]

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.[Abstract/Free Full Text]

Liaw, D., Marsh, D.J., Li, J., Dahia, P.L., Wang, S.I., Zheng, Z., Bose, S., Call, K.M., Tsou, H.C., Peacocke, M., et al. 1997. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16: 64-67.[CrossRef][Medline]

Marsh, D.J., Dahia, P.L., Zheng, Z., Liaw, D., Parsons, R., Gorlin, R.J., and Eng, C. 1997. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat. Genet. 16: 333-334.[CrossRef][Medline]

Nagase, H., Mao, J.H., and Balmain, A. 2003. Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. Cancer Res. 63: 4849-4853.[Abstract/Free Full Text]

Perez-Losada, J. and Balmain, A. 2003. Stem-cell hierarchy in skin cancer. Nat. Rev. Cancer 3: 434-443.[CrossRef][Medline]

Podsypanina, K., Ellenson, L.H., Nemes, A., Gu, J., Tamura, M., Yamada, K.M., Cordon-Cardo, C., Catoretti, G., Fisher, P.E., and Parsons, R. 1999. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. 96: 1563-1568.[Abstract/Free Full Text]

Quintanilla, M., Brown, K., Ramsden, M., and Balmain, A. 1986. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322: 78-80.[Medline]

Segrelles, C., Ruiz, S., Perez, P., Murga, C., Santos, C., Budunova, I.V., Martinez, J., Larcher, F., Slaga, T.J., Gutkind, J.S., et al. 2002. Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 21: 53-64.[CrossRef][Medline]

Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16^INK4a. Cell 88: 593-602.[CrossRef][Medline]

Shan, X., Czar, M.J., Bunnell, S.C., Liu, P., Liu, Y., Schwartzberg, P.L., and Wange, R.L. 2000. Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Mol. Cell. Biol. 20: 6945-6957.[Abstract/Free Full Text]

Stambolic, V., Suzuki, A., de la Pompa, J.L., Brothers, G.M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J.M., Siderovski, D.P., and Mak, T.W. 1998. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.[CrossRef][Medline]

Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K., Lin, H., Ligon, A.H., Langford, L.A., Baumgard, M.L., Hattier, T., Davis, T., et al. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15: 356-362.[CrossRef][Medline]

Suzuki, A., Yamaguchi, M.T., Ohteki, T., Sasaki, T., Kaisho, T., Kimura, Y., Yoshida, R., Wakeham, A., Higuchi, T., Fukumoto, M., et al. 2001. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14: 523-534.[CrossRef][Medline]

Suzuki, A., Itami, S., Ohishi, M., Hamada, K., Inoue, T., Komazawa, N., Senoo, H., Sasaki, T., Takeda, J., Manabe, M., et al. 2003. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res. 63: 674-681.[Abstract/Free Full Text]

Tsao, H., Zhang, X., Fowlkes, K., and Haluska, F.G. 2000. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 60: 1800-1804.[Abstract/Free Full Text]

Tsao, H., Goel, V., Wu, H., Yang, G., and Haluska, F.G. 2004. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 122: 337-341.[CrossRef][Medline]

Vivanco, I. and Sawyers, C.L. 2002. The phosphatidylinositol 3–Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2: 489-501.[CrossRef][Medline]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. Yao, C. L. Alexander, J. A. Quinn, W.-C. Chan, H. Wu, and D. A. Greenhalgh Fos cooperation with PTEN loss elicits keratoacanthoma not carcinoma, owing to p53/p21WAF-induced differentiation triggered by GSK3{beta} inactivation and reduced AKT activity J. Cell Sci., May 15, 2008; 121(10): 1758 - 1769. [Abstract] [Full Text] [PDF]

				K. Iwanaga, Y. Yang, M. G. Raso, L. Ma, A. E. Hanna, N. Thilaganathan, S. Moghaddam, C. M. Evans, H. Li, W.-W. Cai, et al. Pten Inactivation Accelerates Oncogenic K-ras-Initiated Tumorigenesis in a Mouse Model of Lung Cancer Cancer Res., February 15, 2008; 68(4): 1119 - 1127. [Abstract] [Full Text] [PDF]

				K. M. Vasudevan, R. Burikhanov, A. Goswami, and V. M. Rangnekar Suppression of PTEN Expression Is Essential for Antiapoptosis and Cellular Transformation by Oncogenic Ras Cancer Res., November 1, 2007; 67(21): 10343 - 10350. [Abstract] [Full Text] [PDF]

				E. Park, F. Zhu, B. Liu, X. Xia, J. Shen, T. Bustos, S. M. Fischer, and Y. Hu Reduction in I{kappa}B Kinase {alpha} Expression Promotes the Development of Skin Papillomas and Carcinomas Cancer Res., October 1, 2007; 67(19): 9158 - 9168. [Abstract] [Full Text] [PDF]

				W.-J. Oh, V. Rishi, S. Pelech, and C. Vinson Histological and proteomic analysis of reversible H-RasV12G expression in transgenic mouse skin Carcinogenesis, October 1, 2007; 28(10): 2244 - 2252. [Abstract] [Full Text] [PDF]

				R. F.L. O'Shaughnessy, B. Akgul, A. Storey, H. Pfister, C. A. Harwood, and C. Byrne Cutaneous Human Papillomaviruses Down-regulate AKT1, whereas AKT2 Up-regulation and Activation Associates with Tumors Cancer Res., September 1, 2007; 67(17): 8207 - 8215. [Abstract] [Full Text] [PDF]

				G. Wei, S. Ku, G. K. Ma, S. Saito, A. A. Tang, J. Zhang, J.-H. Mao, E. Appella, A. Balmain, and E. J. Huang HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis PNAS, August 7, 2007; 104(32): 13040 - 13045. [Abstract] [Full Text] [PDF]

				C. Blanco-Aparicio, O. Renner, J. F.M. Leal, and A. Carnero PTEN, more than the AKT pathway Carcinogenesis, July 1, 2007; 28(7): 1379 - 1386. [Abstract] [Full Text] [PDF]

				C. Blanco-Aparicio, L. Perez-Gallego, B. Pequeno, J. F.M. Leal, O. Renner, and A. Carnero Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer Carcinogenesis, March 1, 2007; 28(3): 584 - 594. [Abstract] [Full Text] [PDF]

				S. Lu, K. Shen, Y. Wang, S. J. Santner, J. Chen, S.C. Brooks, and Y.A. Wang Atm-haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors Carcinogenesis, April 1, 2006; 27(4): 848 - 855. [Abstract] [Full Text] [PDF]

				D. Yao, C. L. Alexander, J. A. Quinn, M. J. Porter, H. Wu, and D. A. Greenhalgh PTEN Loss Promotes rasHa-Mediated Papillomatogenesis via Dual Up-Regulation of AKT Activity and Cell Cycle Deregulation but Malignant Conversion Proceeds via PTEN-Associated Pathways Cancer Res., February 1, 2006; 66(3): 1302 - 1312. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mao, J.-H. Articles by Balmain, A. Search for Related Content PubMed PubMed Citation Articles by Mao, J.-H. Articles by Balmain, A. Social Bookmarking                   What's this?